Literature DB >> 19342698

The dark side of testosterone deficiency: III. Cardiovascular disease.

Abdulmaged M Traish1, Farid Saad, Robert J Feeley, Andre Guay.   

Abstract

A considerable body of evidence exists suggesting that androgen deficiency contributes to the onset, progression, or both of cardiovascular disease (CVD). The aim of this review is to evaluate the relationships between testosterone (T) deficiency and risk factors of CVD and to discuss the implications of androgen deficiency in men with cardiovascular risk factors. The relationship between androgen deficiency and endothelial function, lipid profiles, inflammatory responses, altered vascular smooth muscle reactivity, and hypertension are discussed with regard to CVD. A comprehensive literature search was carried out with the use of Pub Med from 1980 through 2009, and relevant articles pertinent to androgen deficiency and vascular disease were evaluated and discussed. Low T, whether attributed to hypogonadism or androgen deprivation therapy, in men with prostate carcinoma, produces adverse effects on cardiovascular health. Androgen deficiency is associated with increased levels of total cholesterol, low-density lipoprotein, increased production of proinflammatory factors, and increased thickness of the arterial wall and contributes to endothelial dysfunction. Testosterone supplementation restores arterial vasoreactivity; reduces proinflammatory cytokines, total cholesterol, and triglyceride levels; and improves endothelial function but also might reduce high-density lipoprotein levels. Testosterone is an anabolic hormone with a wide range of beneficial effects on men's health. The therapeutic role of T in men's health, however, remains a hotly debated issue for a number of reasons, including the purported risk of prostate cancer. In view of the emerging evidence suggesting that androgen deficiency is a risk factor for CVD, androgen replacement therapy could potentially reduce CVD risk in hypogonadal men. It should be emphasized, however, that androgen replacement therapy should be done with very thorough and careful monitoring for prostate diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19342698     DOI: 10.2164/jandrol.108.007245

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  58 in total

Review 1.  Metabolic syndrome, androgens, and hypertension.

Authors:  Mohadetheh Moulana; Roberta Lima; Jane F Reckelhoff
Journal:  Curr Hypertens Rep       Date:  2011-04       Impact factor: 5.369

Review 2.  Testosterone and heart failure.

Authors:  Maurizio Volterrani; Giuseppe Rosano; Ferdinando Iellamo
Journal:  Endocrine       Date:  2012-06-24       Impact factor: 3.633

3.  Combined inhibition of aromatase activity and dihydrotestosterone supplementation attenuates renal injury in male streptozotocin (STZ)-induced diabetic rats.

Authors:  Michaele B Manigrasso; R Taylor Sawyer; Zachary M Hutchens; Elizabeth R Flynn; Christine Maric-Bilkan
Journal:  Am J Physiol Renal Physiol       Date:  2012-02-01

Review 4.  The paradox of low BNP levels in obesity.

Authors:  Aldo Clerico; Alberto Giannoni; Simona Vittorini; Michele Emdin
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

5.  Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy.

Authors:  Jacques Baillargeon; Randall J Urban; Yong-Fang Kuo; Kenneth J Ottenbacher; Mukaila A Raji; Fei Du; Yu-Li Lin; James S Goodwin
Journal:  Ann Pharmacother       Date:  2014-07-02       Impact factor: 3.154

6.  Prostate magnetic resonance imaging findings in patients treated for testosterone deficiency while on active surveillance for low-risk prostate cancer.

Authors:  Takeshi Hashimoto; Krishnan Rahul; Toshikazu Takeda; Nicole Benfante; John P Mulhall; Hedvig Hricak; James A Eastham; Hebert Alberto Vargas
Journal:  Urol Oncol       Date:  2016-09-22       Impact factor: 3.498

7.  Testosterone regulates bone response to inflammation.

Authors:  J P Steffens; B S Herrera; L S Coimbra; D N Stephens; C Rossa; L C Spolidorio; A Kantarci; T E Van Dyke
Journal:  Horm Metab Res       Date:  2014-02-13       Impact factor: 2.936

8.  Synthesis of esters of androgens with unsaturated fatty acids for androgen requiring therapy.

Authors:  F Aiello; A Garofalo; A M Aloisi; S Lamponi; A Magnani; A Petroni
Journal:  J Endocrinol Invest       Date:  2012-10-22       Impact factor: 4.256

9.  The role of testosterone in the etiology and treatment of obesity, the metabolic syndrome, and diabetes mellitus type 2.

Authors:  Farid Saad; Louis J Gooren
Journal:  J Obes       Date:  2010-08-10

Review 10.  Welcoming low testosterone as a cardiovascular risk factor.

Authors:  M Maggio; S Basaria
Journal:  Int J Impot Res       Date:  2009-06-18       Impact factor: 2.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.